-transparent.png){kind=logo}
Measurement of serum theophylline concentration is usually recommended before intravenous aminophylline is given to patients taking oral theophylline. Fifty patients with worsening airflow obstruction, all of whom were taking oral theophyllines and who had no contraindication to the use of parenteral aminophylline, were randomly allocated into two groups before treatment was given. The dose of aminophylline was calculated without (group A) and with (group B) knowledge of admission serum theophylline concentration. In group A a regimen incorporating corrections to account for factors affecting theophylline clearance was used in an attempt to represent a "knowledgeable" approach; in group B a formula incorporating the known serum theophylline concentration at the time of admission was used. All loading doses were given over 30 minutes as "mini infusions." The two groups were well matched for age, blood gas tensions, and severity of airflow obstruction. The results for four patients (one from group A and three from group B) were excluded from analysis after completion of the study. In each group the mean admission serum theophylline concentration measured (group A: 8.4 (SD 6.0)mg/l; group B: 7.2 (5.7)mg/l) and the aminophylline doses used (group A: loading bolus 172 (45.5)mg, infusion 815 (198)mg; group B: loading bolus 233(189)mg, infusion 788(214)mg) were similar. Mean serum theophylline concentrations during 24 hours' aminophylline treatment, number of patients with a serum theophylline concentration greater than 20 mg/l, symptoms of toxicity, and outcome were also similar in the two groups. Although satisfactory use of parenteral aminophylline was achieved for most patients without knowledge of serum theophylline concentration at the time of admission to hospital (with the aid of a "knowledgeable" clinical approach and constant infusion pumps), prompt measurement of serum theophylline concentration at the time of admission identified patients with either suboptimal or potentially hazardous theophylline concentrations.
J Wiggins, and
O A Arbab, and
D E Stableforth, and
J G Ayres
March 1997,
American journal of perinatology,
J Wiggins, and
O A Arbab, and
D E Stableforth, and
J G Ayres
November 1980,
European journal of clinical pharmacology,
J Wiggins, and
O A Arbab, and
D E Stableforth, and
J G Ayres
September 1981,
American journal of hospital pharmacy,
J Wiggins, and
O A Arbab, and
D E Stableforth, and
J G Ayres
August 1980,
The Journal of pediatrics,
J Wiggins, and
O A Arbab, and
D E Stableforth, and
J G Ayres
December 1982,
Annals of allergy,
J Wiggins, and
O A Arbab, and
D E Stableforth, and
J G Ayres
June 1979,
Harefuah,
J Wiggins, and
O A Arbab, and
D E Stableforth, and
J G Ayres
October 1984,
British journal of clinical pharmacology,
J Wiggins, and
O A Arbab, and
D E Stableforth, and
J G Ayres
December 1981,
Schweizerische medizinische Wochenschrift,
J Wiggins, and
O A Arbab, and
D E Stableforth, and
J G Ayres
March 1984,
British medical journal (Clinical research ed.),
J Wiggins, and
O A Arbab, and
D E Stableforth, and
J G Ayres
March 1986,
Medicina clinica,
